<div id="readability-page-1"><article><div>, /PRNewswire/ -- Azitra, Inc. (&#34;Azitra&#34;) (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it will present at Biotech Showcase™ taking place in San Francisco, January 12-14, 2026.<img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2555910/Azitra_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="400" height="199" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2555910/Azitra_Logo.jpg"/>During the event, members of Azitra's management team will conduct one-on-one meetings with registered investors and potential partners, showcasing the company's clinical development strategy, recent corporate achievements, and anticipated milestones.Details are as follows:<div><table><tbody><tr><td colspan="1" rowspan="1">Event:</td><td colspan="1" rowspan="1">Biotech Showcase 2026</td></tr><tr><td colspan="1" rowspan="1">Date &amp; Time</td><td colspan="1" rowspan="1">Tuesday, January 13, 2026, 2:30 PM, PT</td></tr><tr><td colspan="1" rowspan="1">Location:</td><td colspan="1" rowspan="1">Hilton San Francisco Union Square, Yosemite C (Ballroom Level)</td></tr><tr><td colspan="1" rowspan="1">Presenter</td><td colspan="1" rowspan="1">Travis Whitfill, Chief Operating Officer</td></tr><tr><td colspan="1" rowspan="1">Registration:</td><td colspan="1" rowspan="1">https://informaconnect.com/biotech-showcase/registration-options/</td></tr></tbody></table></div>About Azitra, Inc. Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. Azitra's lead program, ATR-12, uses an engineered strain of S. epidermidis designed to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. Netherton syndrome may be fatal in infancy with those living beyond a year having profound lifelong challenges. The ATR-12 program includes a Phase 1b clinical trial in adults with Netherton syndrome. ATR-04, Azitra's additional clinical program, utilizes another engineered strain of S. epidermidis for the treatment of EGFR inhibitor (&#34;EGFRi&#34;) associated skin toxicity; a Phase 1/2 clinical trial has been initiated for this program. Azitra has received Fast Track designation from the United States Food and Drug Administration for this program to treat EGFRi associated rash, which impacts approximately 150,000 people in the United States. The ATR-12 and ATR-04 programs were developed from Azitra's proprietary platform of engineered proteins and topical live biotherapeutic products that includes a microbial library comprised of approximately 1,500 bacterial strains. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen the library of strains for drug like molecules. For more information, please visit https://azitrainc.com.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as &#34;aims,&#34; &#34;anticipates,&#34; &#34;believes,&#34; &#34;could,&#34; &#34;estimates,&#34; &#34;expects,&#34; &#34;forecasts,&#34; &#34;goal,&#34; &#34;intends,&#34; &#34;may,&#34; &#34;plans,&#34; &#34;possible,&#34; &#34;potential,&#34; &#34;seeks,&#34; &#34;will,&#34; and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the Company's ability to satisfy closing conditions for the offering, the expected timing of (i) our provision of initial safety data and topline results for the phase 1b trial for our ATR-12, (ii) the abstract detailing the Phase 1/2 clinical trial for our ATR-04 program, (iii) the initiation of dosing in the Phase 1/2 clinical trial for our ATR-04 program, and (iv) statements about our clinical and preclinical programs, and corporate and clinical/preclinical strategies.Any forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the satisfaction of the conditions to closing of the private placement, the timing of clinical trials and their results as we may experience delays in the provision of initial safety data and topline results for ATR-12 or, if we do, that such data may not be favorably received; the safety and efficacy of our product candidates; possible delays in regulatory approval or changes in regulatory framework that are out of our control; our estimation of addressable markets of our product candidates may be inaccurate; we may fail to timely raise additional required funding; more efficient competitors or more effective competing treatment may emerge; we may be involved in disputes surrounding the use of our intellectual property crucial to our success; we may not be able to attract and retain key employees and qualified personnel; earlier study results may not be predictive of later stage study outcomes; and we are dependent on third-parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks concerning Azitra's programs and operations are described or incorporated by reference in our annual report on Form 10-K filed with the United States Securities and Exchange Commission on February 24, 2025. Azitra explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.ContactNorman Staskey Chief Financial Officer staskey@azitrainc.comInvestor Relations Tiberend Strategic Advisors, Inc. Jon Nugent 205-566-3026 jnugent@tiberend.comMedia Relations Tiberend Strategic Advisors, Inc. Casey McDonald 646-577-8520 cmcdonald@tiberend.comSOURCE Azitra, Inc.</div></article></div>

AZTR

Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company, will present at the Biotech Showcase in San Francisco from January 12-14, 2026. The presentation will include one-on-one meetings with investors, highlighting Azitra's clinical development strategy and achievements. Azitra's lead program, ATR-12, targets Netherton syndrome, while ATR-04 addresses EGFR inhibitor-associated skin toxicity. Both programs utilize engineered strains of S. epidermidis and have received Fast Track designation from the FDA. Forward-looking statements regarding clinical trials and regulatory approvals are included in the announcement.

Azitra, Inc. to Present at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference | AZTR Stock News